PeptideStack
5.2kquestions
20kanswers
220users

How do I compare SSA and HJ on lead time to Canada?

Asked 17 Jul 2026Modified 2 days agoViewed 2.4k times
9

For reference: SSA · HJ · Canada.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

What does each option buy me, and what does it cost me?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
international-shipping
international-shipping

Cross-border movement of research material: transit lanes and their thermal profiles, tracked versus untracked, declaration accuracy, and what…

471 questions
cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
shareeditfollowflag
PM
askedpriya_menon13k3517 Jul 2026
Worth saying which country you are in, because the answer is jurisdictional. – bufferline42 8 months ago
add a comment

5 Answers

Accepted answer first, then by votes
10

Accepted answer

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

To be exact about it, lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Price per milligram of measured peptide, not per milligram of label claim.

edited 24 Jul 2026 by w_okoye — corrected a unit error in the worked example

shareimprove this answerflag
WO
answered · acceptedw_okoye43k13718 Jul 2026
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
15

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Use a fixed documentation checklist rather than an impression.

shareimprove this answerflag
IB
answeredines_brandt113k25718 Jul 2026
The point about the code being on the glass rather than the box is worth its own thread. – rhian_prydderch 2 months ago
add a comment
3

This is the question where methodology matters more than the conclusion.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

The caveat is that a comparison is a snapshot of the lots compared, and lots change.

Name the laboratory and the dates or the comparison cannot be reproduced.

shareimprove this answerflag
LW
answeredlinnea_wahlberg17k2728 Jul 2026
2Adding for future readers: ask for the lot-specific certificate before ordering, not after. – h_pergande 6 months ago
3Any view on whether two lots agreeing is worth more than one lot excelling? I think it is. – Dr_Malik_Osei 8 months ago
add a comment
1

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Compare content, not purity. Purity clusters and content does not.

shareimprove this answerflag
IB
answeredines_brandt113k25722 Jul 2026
4Small correction: carriage amortises across the order, which changes small-order economics entirely. – Dr_Bram_Verhoeven 3 months ago
3Confirming that a small first order plus one independent submission is the cheapest route. – claudia_ferrante 2 months ago
add a comment
1

The honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.

Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

The published aggregate datasets from Janoshik, Medutest and PeptideMeter are the closest thing to a systematic evidence base in this space, and the striking pattern across all three is that identity is almost always confirmed, purity is usually acceptable, and content is where the variance lives.

Nothing here is medical advice, and research-use compounds are not approved for human use.

One laboratory, one method, one submission. Otherwise it is not a comparison.

shareimprove this answerflag
OB
answeredone_ml_bac18k2725 Jul 2026
4Worth flagging that comparing across laboratories is comparing laboratories, not suppliers. – m_haraldsen 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.